Chemical inhibitors of C6orf35 can function by disrupting various signaling pathways that regulate the activity of this protein. Staurosporine is a broad-spectrum kinase inhibitor that can inhibit the activity of multiple protein kinases, which may be involved in the phosphorylation and subsequent regulation of C6orf35. By inhibiting these kinases, Staurosporine can prevent the phosphorylation that is necessary for the proper functioning of C6orf35. Similarly, Bisindolylmaleimide I targets Protein Kinase C (PKC), and if PKC-mediated phosphorylation is crucial for C6orf35 activity, this inhibitor can suppress its function. LY294002 and Wortmannin both target PI3K, another kinase that can regulate various proteins by signaling pathways. If C6orf35 operates downstream of PI3K, inhibition by these chemicals can result in the loss of its functional activity.
Additional inhibitors that target specific components of cellular signaling pathways include Rapamycin, which inhibits the mTOR pathway, a central regulator of cell growth and metabolism that might be upstream of C6orf35. PD98059, U0126, and SB203580 are selective inhibitors of components of the MAPK pathways; PD98059 and U0126 inhibit MEK1/2 while SB203580 inhibits p38 MAPK. If C6orf35 is activated by the MAPK/ERK or the p38 MAPK pathways, these inhibitors can suppress its activation. SP600125, which inhibits JNK, another kinase within the stress-activated MAPK pathways, can also result in the inhibition of C6orf35 if it is regulated by JNK signaling. PP2, an inhibitor of Src family tyrosine kinases, can disrupt the regulation of C6orf35 if Src kinase-mediated phosphorylation is involved in its regulation. Lastly, Gefitinib and Lapatinib are inhibitors of tyrosine kinases associated with the EGFR and HER2 pathways; if C6orf35 is dependent on signaling through these receptors, inhibition by these chemicals can lead to a reduction in C6orf35 activity. Each of these inhibitors can interfere with the phosphorylation state or signaling pathways necessary for the functional activity of C6orf35, thereby leading to its functional inhibition.
SEE ALSO...
Items 11 to 12 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. If C6orf35 activity is EGFR pathway-dependent, inhibition by Gefitinib would lead to functional inhibition of C6orf35. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib inhibits HER2 and EGFR tyrosine kinases. If C6orf35 is involved in signaling pathways regulated by HER2 or EGFR, Lapatinib's inhibition of these pathways would result in functional inhibition of C6orf35. |